Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-26 · 1181 Präparate · 62955 Quellenpassagen · 167 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 22
HOS-086328 · Präparat HOS-083284
Smoke cessation
Bupropion 150 100 q12h ↓ 22% ↓ 21%
150 600 q12h ↓ 66% ↓ 62%
Bupropion is primarily metabolised by CYP2B6. Concurrent administration of
bupropion with repeated doses of ritonavir is expected to decrease bupropion levels.
These effects are thought to represent induction of bupropion metabolism.
However, because ritonavir has also been shown to inhibit CYP2B6 in vitro, the
recommended dose of bupropion should not be exceeded. In contrast to long-term
administration of ritonavir, there was no significant interaction with bupropion after
short-term administration of low doses of ritonavir (200 mg twice daily for 2 days),
suggesting reductions in bupropion concentrations may have onset several days after
initiation of ritonavir co-administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 5df30991532aed9c4a46b92f3966cb44666a87fbb03fa46e4bc56a6eca98f939 · Zeichen 54774–56027 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 55
HOS-086489 · Präparat HOS-083284
Smoke cessation
Bupropion 150 100 q12h ↓ 22% ↓ 21%
150 600 q12h ↓ 66% ↓ 62%
Bupropion is primarily metabolised by CYP2B6. Concurrent administration of bupropion
with repeated doses of ritonavir is expected to decrease bupropion levels. These effects
are thought to represent induction of bupropion metabolism. However, because ritonavir
has also been shown to inhibit CYP2B6 in vitro, the recommended dose of bupropion
should not be exceeded. In contrast to long-term administration of ritonavir, there was no
significant interaction with bupropion after short-term administration of low doses of
ritonavir (200 mg twice daily for 2 days), suggesting reductions in bupropion
concentrations may have onset several days after initiation of ritonavir co-administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f83d8576f370ed4770b04d02e3ae3d60fb477b78c855c8f314d6b7bda88482c8 · Zeichen 57225–58475 im Abschnitt
Wechselwirkungen · DaTSCAN
DaTSCAN 74 MBq/ml solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-090541 · Präparat HOS-084079
Ioflupane binds to the dopamine transporter. Medicines that bind to the dopamine transporter with high
affinity may therefore interfere with DaTSCAN diagnosis. These include amfetamine, bupropion,
cocaine, codeine, dexamfetamine, methylphenidate, modafinil, and phentermine. Selective serotonin
reuptake inhibitors (SSRIs), such as sertraline, may increase or decrease ioflupane binding to the
dopamine transporter. Serotonin-norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine, may
decrease ioflupane binding to the dopamine transporter especially in patients on higher doses.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ioflupane (HOS-090542) norepinephrine (HOS-090547) bupropion (HOS-086329) codeine (HOS-090544) modafinil (HOS-090546) dopamine (HOS-085948) methylphenidate (HOS-090545) venlafaxine (HOS-086573) cocaine (HOS-090543) phentermine (HOS-087483) serotonin (HOS-085477) sertraline (HOS-086247)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-25T02:00:00Z · SHA-256 f40f7ad424fba21e279058645a7f9123ad356bfb210f5e9a98e718256e3987ab · Passage b61bee0e5f8e9e99224bcb5a4db13e8cfb7d2e33ddbe5e161cf3103ca90bf479 · Zeichen 55–644 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 25–26
HOS-108940 · Präparat HOS-093083
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of
contraception must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after
levothyroxine. starting and/or ending
lopinavir/ritonavir treatment.
Vasodilating agents
25
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should
AUC: ↑ 5-fold be closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of co-administration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) methadone (HOS-086198) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8d752c4274572732732b0956ff6ff26c5cf23921c5ef2d225aedad5e185afa6d · Zeichen 59817–63890 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 60–61
HOS-109023 · Präparat HOS-093083
60
No clinical relevant interaction fluvastatin or pravastatin is
expected. recommended.
Pravastatin is not metabolised by
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg Buprenorphine: ↔ No dose adjustment necessary.
QD
Methadone Methadone: ↓ Monitoring plasma concentrations of
methadone is recommended.
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of contraception
must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended dosage,
metabolism. despite the observed induction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) methadone (HOS-086198) fluvastatin (HOS-086305) buprenorphine (HOS-086193) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 66795734d42d6453cc3ecae53ffe464f62e190070894ffc9d2f185474a98d737 · Zeichen 57035–59066 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 96–97
HOS-109102 · Präparat HOS-093083
96
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of contraception
must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after starting
levothyroxine. and/or ending lopinavir/ritonavir
treatment.
Vasodilating agents
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should be
AUC: ↑ 5-fold closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of coadministration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage eb717f7573e257a0db9660c2692fa6be3f81b8ac5b4c1043b1f49219b74ffa31 · Zeichen 58967–62731 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 22–23
HOS-114854 · Präparat HOS-094169
22
Bupropion 150 mg BID Bupropion Cmax ↓ 51% If the co-administration with
Bupropion AUC ↓ 56% bupropion is judged unavoidable,
this should be done under close
Tipranavir ↔ clinical monitoring for bupropion
efficacy, without exceeding the
The reduction of bupropion recommended dosage, despite the
plasma levels is likely due to observed induction.
induction of CYP2B6 and UGT
activity by RTV
Loperamide 16 mg QD Loperamide Cmax ↓ 61% A pharmacodynamic interaction
Loperamide AUC ↓ 51% study in healthy volunteers
demonstrated that administration
Mechanism unknown of loperamide and Aptivus, co-
administered with low dose
Tipranavir Cmax ↔ ritonavir, does not cause any
Tipranavir AUC ↔ clinically relevant change in the
Tipranavir Cmin ↓ 26% respiratory response to carbon
dioxide. The clinical relevance of
the reduced loperamide plasma
concentration is unknown.
Fluticasone propionate In a clinical study where ritonavir Concomitant administration of
Interaction study 100 mg capsules bid were co- Aptivus, co-administered with
performed only with administered with 50 µg low dose ritonavir, and these
ritonavir intranasal fluticasone propionate glucocorticoids is not
(4 times daily) for 7 days in recommended unless the
healthy subjects, the fluticasone potential benefit of treatment
propionate plasma levels outweighs the risk of systemic
increased significantly, whereas corticosteroid effects (see
the intrinsic cortisol levels section 4.4). A dose reduction of
decreased by approximately 86% the glucocorticoid should be
(90% confidence interval considered with close monitoring
82-89%). Greater effects may be of local and systemic effects or a
expected when fluticasone switch to a glucocorticoid, which
propionate is inhaled. Systemic is not a substrate for CYP3A4
corticosteroid effects including (e.g. beclomethasone). Moreover,
Cushing’s syndrome and adrenal in case of withdrawal of
suppression have been reported in glucocorticoids progressive dose
patients receiving ritonavir and reduction may have to be
inhaled or intranasally performed over a longer period.
administered fluticasone The effects of high fluticasone
propionate; this could also occur systemic exposure on ritonavir
with other corticosteroids plasma levels are as yet
metabolised via the P450 3A unknown.
pathway e.g. budesonide.
It is unknown whether the
combination of tipranavir with
ritonavir might cause a larger
increase in fluticasone exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) loperamide (HOS-114855) budesonide (HOS-086332) propionate (HOS-108915) ritonavir (HOS-084521) beclomethasone (HOS-086334)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 7522c1a17dc381755410649aa6db82293f9c200ad2f0eeed696045d4a966abe6 · Zeichen 60402–64824 im Abschnitt
Wechselwirkungen · Champix
CHAMPIX 0.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-115913 · Präparat HOS-094383
Bupropion
Varenicline did not alter the steady-state pharmacokinetics of bupropion.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-11T14:06:00Z · SHA-256 512fd3657f567938fdb59e3cf59c59c6c8e3323f46db8617dff61b0f88e2f1f0 · Passage 4ab4b8bca410b8ede1545a5340e8ad87c3c509c235a5591961abfcfca184ff59 · Zeichen 2251–2334 im Abschnitt
Wechselwirkungen · Champix
CHAMPIX 1 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 28
HOS-115943 · Präparat HOS-094383
Bupropion
Varenicline did not alter the steady-state pharmacokinetics of bupropion.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-11T14:06:00Z · SHA-256 512fd3657f567938fdb59e3cf59c59c6c8e3323f46db8617dff61b0f88e2f1f0 · Passage 4ab4b8bca410b8ede1545a5340e8ad87c3c509c235a5591961abfcfca184ff59 · Zeichen 2252–2335 im Abschnitt
Wechselwirkungen · Champix
CHAMPIX 0.5 mg film-coated tablets CHAMPIX 1 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 50
HOS-115972 · Präparat HOS-094383
Bupropion
Varenicline did not alter the steady-state pharmacokinetics of bupropion.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-11T14:06:00Z · SHA-256 512fd3657f567938fdb59e3cf59c59c6c8e3323f46db8617dff61b0f88e2f1f0 · Passage 4ab4b8bca410b8ede1545a5340e8ad87c3c509c235a5591961abfcfca184ff59 · Zeichen 2250–2333 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 375 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-118257 · Präparat HOS-094791
The potential for inhibition of CYP2B6 has not been evaluated. Caution is advised during
co-administration with CYP2B6 substrates (e.g. bupropion, efavirenz, cyclophosphamide).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) cyclophosphamide (HOS-084539) efavirenz (HOS-087947)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 10a55e7638aa40a072e9e70fa9c50e10abefafb9097938a6339bc568f496d4bc · Zeichen 3389–3565 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 500 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 17
HOS-118304 · Präparat HOS-094791
The potential for inhibition of CYP2B6 has not been evaluated. Caution is advised during
co-administration with CYP2B6 substrates (e.g. bupropion, efavirenz, cyclophosphamide).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) cyclophosphamide (HOS-084539) efavirenz (HOS-087947)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 10a55e7638aa40a072e9e70fa9c50e10abefafb9097938a6339bc568f496d4bc · Zeichen 3391–3567 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 750 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-118346 · Präparat HOS-094791
The potential for inhibition of CYP2B6 has not been evaluated. Caution is advised during
co-administration with CYP2B6 substrates (e.g. bupropion, efavirenz, cyclophosphamide).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) cyclophosphamide (HOS-084539) efavirenz (HOS-087947)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 10a55e7638aa40a072e9e70fa9c50e10abefafb9097938a6339bc568f496d4bc · Zeichen 3390–3566 im Abschnitt
Wechselwirkungen · Efient
Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6
HOS-120780 · Präparat HOS-095209
Medicinal products metabolised by CYP2B6:
Prasugrel is a weak inhibitor of CYP2B6. In healthy subjects, prasugrel decreased exposure to
hydroxybupropion, a CYP2B6-mediated metabolite of bupropion, by 23%. This effect is likely to be
of clinical concern only when prasugrel is co-administered with medicinal products for which
CYP2B6 is the only metabolic pathway and have a narrow therapeutic window
(e.g. cyclophosphamide, efavirenz).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) cyclophosphamide (HOS-084539) efavirenz (HOS-087947)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-22T14:15:00Z · SHA-256 bf0eaa99dea4480cd15ea241fb41ce985dc8e97851472df117f97dc0c795a95e · Passage fb8215c833ca7cbd9c31808c5ccc00ec508cce92747df1a4d5c640d188d8341f · Zeichen 4956–5391 im Abschnitt
Wechselwirkungen · Firdapse (previously Zenas)
FIRDAPSE 10 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-210246 · Präparat HOS-154477
Medicinal products known to lower the epileptic threshold
The concomitant use of amifampridine and substances known to lower the epileptic threshold may
lead to an increased risk of seizures. The decision to administer proconvulsant or epileptic-threshold
lowering substances concomitantly should be carefully considered in the light of the severity of the
associated risks. These substances include most anti-depressants (tricyclic antidepressants, selective
serotonin uptake inhibitors), neuroleptics (phenothiazines and butyrophenones), mefloquine,
bupropion and tramadol (see sections 4.4 and 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) lead (HOS-085592) serotonin (HOS-085477) mefloquine (HOS-113850) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-05-25T11:00:00Z · SHA-256 92cbbf47b9125cbf72b4c63d78ca50f05a820bbcbe9f450c757171186f057752 · Passage f62afcf92eea0df25ca44cb5864e21dd6960517614004477c8d3727cb9318191 · Zeichen 2275–2877 im Abschnitt
Wechselwirkungen · Tepadina
TEPADINA 15 mg powder for concentrate for solution for infusion TEPADINA 100 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-210371 · Präparat HOS-154509
Thiotepa is a weak inhibitor for CYP2B6, and may thereby potentially increase plasma concentrations
of substances metabolised via CYP2B6, such as ifosfamide, tamoxifen, bupropion, efavirenz and
cyclophosphamide. CYP2B6 catalyzes the metabolic conversion of cyclophosphamide to its active
form 4-hydroxycyclophosphamide (4-OHCP) and co-administration of thiotepa may therefore lead to
decreased concentrations of the active 4-OHCP. Therefore, a clinical monitoring should be exercised
during the concomitant use of thiotepa and these medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) tamoxifen (HOS-088380) ifosfamide (HOS-091529) lead (HOS-085592) cyclophosphamide (HOS-084539) efavirenz (HOS-087947) 4-hydroxycyclophosphamide (HOS-210375)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T14:00:00Z · SHA-256 42c8bab87a55159cb982d55f577a064273549ce149f75b75dbf4d5650be413bc · Passage 02fee406a06fed33cf20b2e58b8f5c3da3663e1afa93c280704add454e4e3420 · Zeichen 992–1544 im Abschnitt
Wechselwirkungen · Tepadina
TEPADINA 200 mg powder and solvent for solution for infusion TEPADINA 400 mg powder and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 24
HOS-210415 · Präparat HOS-154509
Thiotepa is a weak inhibitor for CYP2B6, and may thereby potentially increase plasma concentrations
of substances metabolised via CYP2B6, such as ifosfamide, tamoxifen, bupropion, efavirenz and
cyclophosphamide. CYP2B6 catalyzes the metabolic conversion of cyclophosphamide to its active
form 4-hydroxycyclophosphamide (4-OHCP) and co-administration of thiotepa may therefore lead to
decreased concentrations of the active 4-OHCP. Therefore, a clinical monitoring should be exercised
during the concomitant use of thiotepa and these medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) tamoxifen (HOS-088380) ifosfamide (HOS-091529) lead (HOS-085592) cyclophosphamide (HOS-084539) efavirenz (HOS-087947) 4-hydroxycyclophosphamide (HOS-210375)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T14:00:00Z · SHA-256 42c8bab87a55159cb982d55f577a064273549ce149f75b75dbf4d5650be413bc · Passage 02fee406a06fed33cf20b2e58b8f5c3da3663e1afa93c280704add454e4e3420 · Zeichen 992–1544 im Abschnitt
Wechselwirkungen · Methylthioninium chloride Proveblue
Methylthioninium chloride Proveblue 5 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-213653 · Präparat HOS-155158
Methylthioninium chloride should be avoided in patients receiving medicinal products that enhance
serotonergic transmission because of the potential for serious CNS reactions, including potentially fatal
serotonin syndrome. These include SSRIs (selective serotonin reuptake inhibitors), bupropion,
buspirone, clomipramine, mirtazapine, and venlafaxine. Opioids, for example, tramadol, fentanyl,
pethidine, and dextromethorphan, may also increase the risk of developing serotonin syndrome, when
used in combination with methylthioninium chloride. If the intravenous use of methylthioninium
chloride cannot be avoided in patients treated with serotonergic medicinal products, the lowest possible
dose should be chosen and the patient observed closely for central nervous system (CNS) effects for up
to 4 hours after administration (see sections 4.4 and 4.8).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) venlafaxine (HOS-086573) serotonin (HOS-085477) clomipramine (HOS-085906) mirtazapine (HOS-144406) buspirone (HOS-086325) fentanyl (HOS-086196) dextromethorphan (HOS-109265) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-19T17:19:00Z · SHA-256 19c53bf82f55a8d25e4c6a9ce5fce20575d1af796cef659dc721231268971317 · Passage 5d108e81ebe37e06fa7a97ec420e29ae2832486a9d97d04b89c9ed6e3c9daf74 · Zeichen 0–856 im Abschnitt
Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-215304 · Präparat HOS-155418
Efavirenz:
AUC: ↔
Cmax: ↑ 11% (↑ 6 to ↑ 16)
Cmin: ↔
(CYP3A4 induction)
Paroxetine/efavirenz No clinically significant No dose adjustment is necessary
(20 mg once daily/600 mg once pharmacokinetic interaction for either medicinal product.
daily)
Fluoxetine/efavirenz Interaction not studied. Since No dose adjustment is necessary
fluoxetine shares a similar metabolic for either medicinal product.
profile with paroxetine, i.e. a strong
CYP2D6 inhibitory effect, a similar
lack of interaction would be expected
for fluoxetine.
Norepinephrine and dopamine reuptake inhibitor
Bupropion/efavirenz Bupropion: Increases in bupropion dosage
[150 mg single dose (sustained AUC: ↓ 55% (↓ 48 to ↓ 62) should be guided by clinical
release)/600 mg once daily] Cmax: ↓ 34% (↓ 21 to ↓ 47) response, but the maximum
recommended dose of bupropion
Hydroxybupropion:
should not be exceeded. No dose
AUC: ↔ adjustment is necessary for
Cmax: ↑ 50% (↑ 20 to ↑ 80) efavirenz.
(CYP2B6 induction)
ANTIHISTAMINES
Cetirizine/efavirenz Cetirizine: No dose adjustment is necessary
(10 mg single dose/600 mg once AUC: ↔ for either medicinal product.
daily) Cmax: ↓ 24% (↓ 18 to ↓ 30)
These changes are not considered
clinically significant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) norepinephrine (HOS-090547) bupropion (HOS-086329) dopamine (HOS-085948) fluoxetine (HOS-085946) cetirizine (HOS-215305)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage f6abe2540d545b6a7b0c3b11a7d04068ce9f1e9463270db973d45e56e0d79fa2 · Zeichen 45029–47167 im Abschnitt
Wechselwirkungen · Zelboraf
Zelboraf 240 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 8
HOS-215547 · Präparat HOS-155464
Mild induction of CYP2B6 by vemurafenib was noted in vitro at a vemurafenib concentration of
10 µM. It is currently unknown whether vemurafenib at a plasma level of 100 µM observed in patients
at steady state (approximately 50 µg/ml) may decrease plasma concentrations of concomitantly
administered CYP2B6 substrates, such as bupropion.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-19T10:15:00Z · SHA-256 2d456fa760308f0a3cd38ceefcce188400597f529dcb630f5163ed6664af53db · Passage dfa25c22444819fffc6328d7721035f33d8fbe811fa96b244501471fde33000c · Zeichen 1667–2003 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.